Literature DB >> 21409613

Guidelines 2.0: do no net harm-the future of practice guideline development in asthma and other diseases.

Holger J Schünemann1.   

Abstract

Decisions are like double-edged swords: they always come with benefits and downsides. That is, any decision in life bears desirable and undesirable consequences, even if the latter only involves the time it takes to make or think about the decision, which can be considered the harm of decision making. Therefore, it is impossible to adhere to the Hippocratic Oath's concept of "primum non nocere," which is frequently interpreted as "never do harm." The guiding principle for health care decision making should be to ensure that there is, in summary, more benefit than harm-in other words, "to do no net harm" ("primum non net nocere"). Practice guidelines support decision making and, as a consequence, would require the explicit consideration of both desirable and undesirable consequences, and assigning due considerations depending on the magnitude and importance of the consequences. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group ( http://www.gradeworkinggroup.org ) has made these considerations more explicit when developing health care recommendations. This article briefly summarizes the work of the GRADE working group based on examples of its application in the field of allergy and asthma, and provides an outlook for advances in the field of guideline development. These developments focus on funding of guidelines and handling conflict of interest, working with observational and diagnostic test accuracy studies, developing appropriate group processes, and the integration of values and preferences in the formulation of recommendations.

Entities:  

Mesh:

Year:  2011        PMID: 21409613     DOI: 10.1007/s11882-011-0185-8

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  38 in total

1.  Practice guidelines developed by specialty societies: the need for a critical appraisal.

Authors:  R Grilli; N Magrini; A Penna; G Mura; A Liberati
Journal:  Lancet       Date:  2000-01-08       Impact factor: 79.321

Review 2.  Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials.

Authors:  Gordon C S Smith; Jill P Pell
Journal:  BMJ       Date:  2003-12-20

3.  A framework for mandatory impact evaluation to ensure well informed public policy decisions.

Authors:  Andrew D Oxman; Arild Bjørndal; Francisco Becerra-Posada; Mark Gibson; Miguel Angel Gonzalez Block; Andy Haines; Maimunah Hamid; Carmen Hooker Odom; Haichao Lei; Ben Levin; Mark W Lipsey; Julia H Littell; Hassan Mshinda; Pierre Ongolo-Zogo; Tikki Pang; Nelson Sewankambo; Francisco Songane; Haluk Soydan; Carole Torgerson; David Weisburd; Judith Whitworth; Suwit Wibulpolprasert
Journal:  Lancet       Date:  2010-01-30       Impact factor: 79.321

4.  Final report of the Lyme disease review panel of the Infectious Diseases Society of America.

Authors:  Paul M Lantos; William A Charini; Gerald Medoff; Manuel H Moro; David M Mushatt; Jeffrey Parsonnet; John W Sanders; Carol J Baker
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

5.  Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings.

Authors:  Peter Lurie; Cristina M Almeida; Nicholas Stine; Alexander R Stine; Sidney M Wolfe
Journal:  JAMA       Date:  2006-04-26       Impact factor: 56.272

6.  Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.

Authors:  Peter Q Eichacker; Charles Natanson; Robert L Danner
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

7.  When are randomised trials unnecessary? Picking signal from noise.

Authors:  Paul Glasziou; Iain Chalmers; Michael Rawlins; Peter McCulloch
Journal:  BMJ       Date:  2007-02-17

8.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

9.  Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement.

Authors:  Holger J Schünemann; Atle Fretheim; Andrew D Oxman
Journal:  Health Res Policy Syst       Date:  2006-12-05

Review 10.  WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.

Authors:  Holger J Schünemann; Suzanne R Hill; Meetali Kakad; Richard Bellamy; Timothy M Uyeki; Frederick G Hayden; Yazdan Yazdanpanah; John Beigel; Tawee Chotpitayasunondh; Chris Del Mar; Jeremy Farrar; Tinh Hien Tran; Bülent Ozbay; Norio Sugaya; Keiji Fukuda; Nikki Shindo; Lauren Stockman; Gunn E Vist; Alice Croisier; Azim Nagjdaliyev; Cathy Roth; Gail Thomson; Howard Zucker; Andrew D Oxman
Journal:  Lancet Infect Dis       Date:  2007-01       Impact factor: 25.071

View more
  5 in total

1.  Ten things you should consider before you believe a clinical practice guideline.

Authors:  R Jaeschke; G H Guyatt; H Schünemann
Journal:  Intensive Care Med       Date:  2014-12-17       Impact factor: 17.440

2.  The GRADE Working Group clarifies the construct of certainty of evidence.

Authors:  Monica Hultcrantz; David Rind; Elie A Akl; Shaun Treweek; Reem A Mustafa; Alfonso Iorio; Brian S Alper; Joerg J Meerpohl; M Hassan Murad; Mohammed T Ansari; Srinivasa Vittal Katikireddi; Pernilla Östlund; Sofia Tranæus; Robin Christensen; Gerald Gartlehner; Jan Brozek; Ariel Izcovich; Holger Schünemann; Gordon Guyatt
Journal:  J Clin Epidemiol       Date:  2017-05-18       Impact factor: 6.437

3.  Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?

Authors:  Bram Rochwerg; Holger J Schünemann; Ganesh Raghu
Journal:  BMC Med       Date:  2016-02-10       Impact factor: 8.775

Review 4.  Defining certainty of net benefit: a GRADE concept paper.

Authors:  Brian S Alper; Peter Oettgen; Ilkka Kunnamo; Alfonso Iorio; Mohammed Toseef Ansari; M Hassan Murad; Joerg J Meerpohl; Amir Qaseem; Monica Hultcrantz; Holger J Schünemann; Gordon Guyatt
Journal:  BMJ Open       Date:  2019-06-04       Impact factor: 2.692

5.  Defining decision thresholds for judgments on health benefits and harms using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision (EtD) frameworks: a protocol for a randomised methodological study (GRADE-THRESHOLD).

Authors:  Gian Paolo Morgano; Lawrence Mbuagbaw; Nancy Santesso; Feng Xie; Jan L Brozek; Uwe Siebert; Antonio Bognanni; Wojtek Wiercioch; Thomas Piggott; Andrea J Darzi; Elie A Akl; Ilse M Verstijnen; Elena Parmelli; Zuleika Saz-Parkinson; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ Open       Date:  2022-03-10       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.